Latest Updates on Lilly's Inluriyo and Its Efficacy in Breast Cancer Treatment Eli Lilly reveals promising new data from the EMBER-3 study, showcasing the efficacy of Inluriyo both alone and in combination with Verzenio for advanced breast cancer patients.

Latest Updates on Lilly's Inluriyo and Its Efficacy in Breast Cancer Treatment #USA #Indianapolis #Eli_Lilly #Verzenio #Inluriyo

Eli Lilly Showcases Key Programs in Hormone Receptor-Positive Breast Cancer at 2025 SABCS Eli Lilly is set to present groundbreaking data on hormone receptor-positive breast cancer programs at the upcoming 2025 SABCS in San Antonio, Texas.

Eli Lilly Showcases Key Programs in Hormone Receptor-Positive Breast Cancer at 2025 SABCS #United_States #San_Antonio #Eli_Lilly #Verzenio #Inluriyo

#EliLilly's CDK4/6 inhibitor #Verzenio reduced the risk of death by 15.8% when used as adjuvant treatment for early-stage HR-positive, HER2-negative #breastcancer, according the reveal of data from the #monarchEtrial.

pharmaphorum.com/news/esmo-li...

Lilly's Verzenio®: A Breakthrough in Breast Cancer Survival Rates after Two Years of Treatment Lilly's Verzenio® has shown remarkable improvement in survival rates for patients with HR+, HER2- early breast cancer after two years of treatment, marking a significant advancement in oncology.

Lilly's Verzenio®: A Breakthrough in Breast Cancer Survival Rates after Two Years of Treatment #United_States #Indianapolis #Breast_Cancer #Verzenio #Lilly

Lilly to Unveil Promising Clinical Findings for Verzenio and New Pipeline Developments at ESMO 2025 At the upcoming ESMO 2025, Lilly will showcase new clinical findings for Verzenio and various innovations in cancer treatment. Learn more about these promising advancements.

Lilly to Unveil Promising Clinical Findings for Verzenio and New Pipeline Developments at ESMO 2025 #Germany #Berlin #Verzenio #Lilly #ESMO_2025

Abemaciclib Boosts Survival in High-Risk HR+, HER2- BC Verzenio® (Abemaciclib) improves overall survival in high-risk HR+, HER2- early BC. MonarchE trial results and its impact on treatment.

Press Release: Verzenio (Abemaciclib) Increases Overall Survival in High-Risk HR+, HER2- Early BC.

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Verzenio #Abemaciclib #BC #BreastCancer

Meme kanseri hapında 7 yıllık denemeden umut verici sonuç Faz 3 klinik çalışmaya göre Verzenio, lenf düğümlerine yayılmış yüksek riskli erken evre meme kanseri hastalarında nüks riskini belirgin şekilde azalttı. TRT Haber'in Sciencealert'tan aktardığı habere göre, 5 bin 637 hasta üzerinde yürütülen denemede, yalnızca hormon tedavisi alanlara kıyasla Verzenio ile kombine tedavi görenlerde sağkalım oranı anlamlı ölçüde arttı. Henüz hakemli dergilerde yayımlanmayan sonuçlar, önümüzdeki dönemde bilimsel kongrelerde paylaşılacak. FDA ONAYI VE GENİŞLEYEN KULLANIM Verzenio, ABD Gıda ve İlaç Dairesi (FDA) tarafından ilk kez 2017’de ileri evre veya metastatik meme kanseri için onaylandı. Hormon reseptörü pozitif (HR+), HER2-negatif hastalarda kullanılan ilaç, 2023’te erken evre yüksek riskli vakalara da onay aldı.Bu tip kanser, tüm meme kanseri vakalarının yaklaşık yüzde 70–80’ini oluşturuyor. HR+ tümörler, östrojen ve progesteron gibi hormonlarla etkileşerek büyüyor. Verzenio ise hücre bölünmesinden sorumlu enzimleri baskılayarak tümör çoğalmasını durduruyor. UZMANLARDAN DEĞERLENDİRME Lilly Oncology Başkanı Jacob Van Naarden, “Bu veriler, Verzenio’nun yüksek riskli HR+, HER2-negatif erken evre meme kanserinde standart tedavi olarak önemini doğruluyor. Hastaların hastalığın tekrarlamasını engellemek ve yaşam süresini uzatmak en yüksek hedefimiz.” ifadelerini kullandı.Sadece geçen yıl 5,3 milyar dolar satış yapan ilaç, Lilly’nin en önemli kanser tedavilerinden biri haline geldi. MEME KANSERİNDE FARKLI ALT TİPLER HR+, HER2-negatif: En sık görülen ve tedaviye en iyi yanıt veren tip. Üçlü negatif (Triple-negative): En agresif tür; hormon ve HER2 reseptörleri bulunmadığı için tedavisi zor. Yeni veriler, HR+ ve HER2-negatif hastalarda nüksü önlemede iki yıllık Verzenio + hormon tedavisinin güçlü bir fark yarattığını ortaya koyuyor. Kaynak: HABER7.COM #ESHAHABER.COM.TR #haber #gündem #sondakika #news #press #worldnews

Güncel News press Meme kanseri hapında 7 yıllık denemeden umut verici sonuç #memeKanseri #Verzenio #kanserAraştırmaları #sağkalım #klinikAraştırma

Lilly raises stakes in Novartis battle with Verzenio data Armed with new survival data for Verzenio in early breast cancer, Lilly hopes to keep the drug's nose in front of a fast-growing rival from Novartis.

Armed with new survival data from the monarchE trial of CDK4/6 inhibitor #Verzenio, #EliLilly looks set to cement the drug's place in the treatment of early-stage #breastcancer, and keep its nose in front of a fast-growing rival from Novartis.

pharmaphorum.com/news/lilly-r...

Lilly's Verzenio® Shows Improved Survival Rates in High-Risk Early Breast Cancer Patients Recent findings demonstrate that Verzenio combined with endocrine therapy significantly enhances overall survival for high-risk early breast cancer patients.

Lilly's Verzenio® Shows Improved Survival Rates in High-Risk Early Breast Cancer Patients #USA #Indianapolis #Breast_Cancer #Eli_Lilly #Verzenio

Verzenio Patient Tips: 7 things you should know Easy-to-read patient tips for Verzenio covering how it works, benefits, risks, and best practices.

Verzenio treats HR+ HER2- breast cancer by targeting cancer cell growth. Diarrhea affects up to 90% of patients in the first month but is manageable with antidiarrheals. Important treatment option for early high-risk and advanced cases. #Verzenio

Verzenio Patient Tips: 7 things you should know Easy-to-read patient tips for Verzenio covering how it works, benefits, risks, and best practices.

#Verzenio (abemaciclib): Targeted Breast Cancer Treatment
Reduces cancer cell growth
For high-risk early & metastatic breast cancer
HR+ HER2- specific
Important note: Diarrhea affects up to 90% of patients in first month, but is typically manageable.

The Rise of VERZENIO: A Key Player in the Growing CDK4/6 Inhibitor Market This article explores the market potential of VERZENIO, a CDK4/6 inhibitor, and its anticipated growth in both breast and prostate cancer treatments.

The Rise of VERZENIO: A Key Player in the Growing CDK4/6 Inhibitor Market #USA #Las_Vegas #Eli_Lilly #Verzenio #CDK4/6_inhibitors

Eli Lilly Joins Forces with Scorpion Therapeutics in $2.5 Billion Cancer Drug Deal Eli Lilly and Co. is making waves in the oncology world with its bold move to acquire Scorpion Therapeutics' experimental PI3K inhibitor for a staggering $2.

www.linkedin.com/pulse/eli-li...

Eli Lilly Joins Forces with Scorpion Therapeutics in $2.5 Billion Cancer Drug Deal

kstrategyand.com/pharma-news

#EliLilly #ScorpionTherapeutics #MedicalInnovation #Healthcare #PharmaPartnerships #Verzenio #BiotechNews #Humanteconomy #Humantec #KStrategyand

Verzenio: 7 things you should know - Drugs.com Quick easy-to-read overview of Verzenio. Includes: how it works, upsides, downsides, bottom line, tips, response and effectiveness.

Breast cancer drug #Verzenio helps stop cancer cells from growing in high-risk early & advanced breast cancers. While very effective, most patients experience manageable diarrhea in the first month of treatment.

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer | NEJM Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (E...

Oral SERD #Imlunestrant in #EMBER3 is shifting the game! No need to check for ESR1 mutations when combined with #verzenio, as revealed by @breastcancerdoc.bsky.social at @sabcs.bsky.social Insightful discussion by @DrBurstein #BreastCancer #OncologyBreakthroughs

www.nejm.org/doi/full/10....

Lilly's Imlunestrant Shows Promising Results in Advanced Breast Cancer Treatment with Improved Survival Rates Recent studies reveal that Lilly's imlunestrant significantly enhances progression-free survival in ER+, HER2- breast cancer patients. The combination with Verzenio offers even better outcomes.

Lilly's Imlunestrant Shows Promising Results in Advanced Breast Cancer Treatment with Improved Survival Rates #USA #Indianapolis #Breast_Cancer #Imlunestrant #Verzenio

Redirecting...

I recently finished, after 2 years, on #verzenio. I was also on 2x100mg. It was very rough on my GI system and towards the end I started taking antinausea daily. This is a great FB group with lots of 💩 talk www.facebook.com/share/g/17mC...

Anyone else on #Verzenio? Love to compare notes on the side effects. I’ve been on the 100mg 2X day for a year. #ILCBC #cansky

Posting some tags for connections coming over from the dead bird 🐦#breastcancer #lobularBC #ILC #Lymphedema #aromataseinhibitors #exemestane #Verzenio #FESPETCT #BCTreatment #Scanxiety #BCchemo #BCradiation #Prolia